Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ALPS GroupALPS -2.73%10 Market Cap is $80.41 Mil as of Jul. 15, 2026. GuruFocus rates ALPS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, ALPS Group ranks worse than 55.87% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ALPS Group's share price for the quarter that ended in Sep. 2025 was $0. ALPS Group's Shares Outstanding (EOP) for the quarter that ended in Sep. 2025 was 166.40 Mil. Therefore, ALPS Group's market cap for the quarter that ended in Sep. 2025 was $0.00 Mil.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ALPS Group's Enterprise Value for Today is $79.96 Mil.
ALPS Group (NAS:ALPS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ALPS Group Market Cap Related Terms
ALPS Group Market Cap Historical Data
* Premium members only.
The historical data trend for ALPS Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPS Group Market Cap Chart
ALPS Group Annual Data
Trend
Mar23
Mar24
Mar25
Market Cap
0.00
0.00
0.00
ALPS Group Semi-Annual Data
Mar23
Mar24
Sep24
Mar25
Sep25
Market Cap
0.00
0.00
0.00
0.00
0.00
ALPS vs CUE, AARD, KLRS: Market Cap Comparison
For the Biotechnology subindustry, ALPS Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALPS Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALPS Group's Market Cap distribution charts can be found below:
* The bar in red indicates where ALPS Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ALPS Group's Market Cap for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPS Group (ALPS) has a Market Cap of $80.41 Mil as of Jul. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ALPS Group and its competitors. According to the industry distribution chart, ALPS Group ranks #795 out of 1423 companies in the Biotechnology industry, placing it in the top 55.9%.
Is ALPS Group's Market Cap too high?
ALPS Group's current Market Cap is $80.41 Mil. The Biotechnology industry median Market Cap is 114.24. ALPS Group's value of $80.41 Mil is 29.6% below this industry median. Based on the distribution chart, ALPS Group ranks #795 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ALPS Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does ALPS Group's Market Cap compare to CUE and AARD?
According to the Biotechnology industry distribution chart, ALPS Group ranks #795 out of 1423 companies for Market Cap. This places ALPS Group in the lower half of its industry. The industry median Market Cap is 114.24. ALPS Group's value of $80.41 Mil is 29.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.24, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ALPS Group's current Market Cap of $80.41 Mil is 29.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ALPS Group and its competitors. For the Biotechnology industry, the median Market Cap is 114.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALPS Group's current Market Cap is $80.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALPS Group stock overvalued right now?
ALPS Group (ALPS) has a current Market Cap of $80.41 Mil. The current Market Cap is $80.41 Mil and 29.6% below the Biotechnology industry median of 114.24. ALPS Group's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ALPS Group (ALPS), the current Market Cap is $80.41 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
10GF Score
Get the complete analysis for ALPS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPS has been successfully added to your 
